This past weekend, leaders of the world’s major economies gathered in Hamburg, Germany, for this year’s G20 Summit. Among the issues on the agenda: safeguarding against health crises and strengthening health systems.

Dr. Jan Holmgren Receives 2017 Albert B. Sabin Gold Medal Award

WASHINGTON, D.C. – April 25, 2017 – Tonight, the Sabin Vaccine Institute (Sabin) will honor Dr. Jan Holmgren with the 2017 Albert B. Sabin Gold Medal Award. Dr. Holmgren will be recognized for his pioneering contributions to oral vaccine research and mucosal immunology, as well as his leadership in the discovery of the world's first effective oral cholera vaccine.

An estimated two billion people lack the medicines they need. The 2016 Access to Medicines Index analyzes pharmaceutical companies’ efforts to improve access to medicines, vaccines and diagnostics for low- and middle-income countries.

Sabin Vaccine Institute President Dr. Peter Hotez gave the keynote address on NTDs at the Pontifical Council for Health Care Workers’ XXXI International Conference, focused on NTDs and rare diseases.

Sabin PDP Begins Phase 1 Clinical Trial to Co-Administer Two Novel Hookworm Vaccine Candidates in Brazil

WASHINGTON, D.C. — April 28, 2016 — The Sabin Vaccine Institute (Sabin) today announced that its Product Development Partnership (Sabin PDP) began a Phase 1 clinical trial of Na-APR-1 (M74)/Alhydrogel® co-administered with Na-GST-1/Alhydrogel in Brazilian adults.

This article was originally posted on the DSW Blog.

By the Dengue Vaccine Initiative

Statement on the World Health Organization’s Declaration of a Public Health Emergency International Concern for Zika Virus

WASHINGTON, D.C. — Feb. 8, 2016 — On Monday, the World Health Organization (WHO) Director-General, Dr. Margaret Chan, declared Zika a Public Health Emergency International Concern (PHEIC), because of growing concerns of the suspected association between Zika and the rise in detected cases of congenital malformations and neurological complications in newborn babies.

Statement by the Dengue Vaccine Initiative on the Philippines Regulatory Approval of Sanofi Pasteur’s Dengue Vaccine, Dengvaxia®

December 22, 2015 — The Philippines yesterday became the first Asian country to approve Sanofi Pasteur’s dengue vaccine, Dengvaxia®, marking the second time in less than one month that a dengue vaccine has been licensed for use in a country.

Pages